在可手术的非小细胞肺癌(NSCLC)患者中,新辅助治疗ipilimumab+nivolumab(Ipi+Nivo)和nivolumab+化疗(Nivo+CT)比单独使用CT诱发更大的病理反应率。 SCI 30 March 2023 Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial (...
BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMBhighcohort.doi:10.1200/JCO.2024.42.16_suppl.809918099#Background:Therapeutic options and prognosis for patients with small-cell lung cancer (SCLC) remain poor. Treatment with checkpoint inhibition can ...
在CheckMate 743 中,nivolumab + ipilimumab 改善了症状负担并维持了整体健康状况,中位随访时间为 29.7 个月。如 LCSS-Meso ASBI 和 3-IGI 以及 EQ-5D-3L VAS 和 UI 最终恶化的时间所见,相比于nivolumab + ipilimumab 组,化疗组的...
因此此,虽然pCR患者的长期无病状态令人欣喜,但对可切除NSCLC患者的新辅助用药nivolumab联合ipilimumab治疗,亟需进一步研究预测性病理反应性的生物标志物。 BACKGROUND: We conducted the first trial of neoadjuvant PD-1 blockade in resectable non-s...
《Journal ofImmunotherapyCancer》2023年7月刊载The University of Texas MD Anderson Cancer Center, Houston, 的Mehmet Altan , Yan Wang , Juhee Song ,等撰写的《Nivolumab和ipilimumab联合立体定向放射外科治疗非小细胞肺癌颅内转移:非随机、非盲、I/II期试验的安全性队列分析。Nivolumab and ipilimumab with concur...
combination of nivolumab and ipilimumab showed a promising rate of 12-week disease control among patients with recurrent malignant pleural mesothelioma, according to interim results of a phase 2 study presented at International Association for the Study of ...
2020年5月27日,FDA批准nivolumab / ipilimumab联合2周期含铂双药化疗用于一线治疗转移性或复发性非小细胞肺癌(NSCLC)且无EGFR或ALK基因变异的患者。 这项批准基于3期CheckMate-9LA临床试验的结果,在该试验中,nivolumab/小剂量的ipilimumab伴随2周期化疗,与单独化疗最多4周期后联合可选择的维持治疗相比,有更长的总生存...
在接受至少一剂新辅助ICIS试验的44名患者(ITT)中,39名患者在试验前后接受了治疗性手术,5名患者没有接受手术(11%,n=1个nivolumab;n=4个nivolumab+ipilimumab)(扩展数据图2)。在39例接受切除的患者中,37例(95%)接受了试验中的手术(n=21例nivolumab;n=16例nivolumab+ipilimumab),2例(5%)在接受额外的系统治疗...
Compared to platinum-based therapies, a combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) has demonstrated improved outcomes in advanced non-small cell lung cancer (NSCLC), albeit with higher rates of immune-related adverse events (irAEs). This multicenter retrospective study ...
BARCELONA — The combination oflow-dose, weight-based ipilimumab and flat-dose nivolumabdemonstrated safety and efficacy as first-line treatment for patients with stage IV non-small cell lung cancer and comorbidities that traditionally preclu...